Rapid health technology assessment of tegoprazan in the treatment of acid-related diseases
This rapid health technology assessment concludes that tegoprazan is a cost-effective, non-inferior alternative to proton pump inhibitors for treating acid-related diseases, offering comparable efficacy with fewer common gastrointestinal side effects but requiring monitoring for potential liver function abnormalities.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your stomach is a busy kitchen, and the chef inside is constantly whipping up a powerful cleaning agent called stomach acid. Usually, this acid is helpful, breaking down your lunch into energy. But sometimes, the chef gets a little too excited, splashing acid everywhere it shouldn't be—up into your throat or into the soft lining of your stomach. This overzealous splashing causes a group of annoying problems known as "acid-related diseases," like heartburn, ulcers, or an infection called H. pylori that loves to hang out in that acidic soup. For years, the standard way to calm this chef down was with a class of drugs called Proton Pump Inhibitors (PPIs). Think of PPIs as a "pause button" for the acid factory; they work well, but they can be a bit slow to start, sometimes inconsistent, and they don't always stay on long enough to stop the acid from sneaking back up at night. Recently, a new type of drug called a Potassium-Competitive Acid Blocker (P-CAB) has entered the scene. These are like a super-charged, fast-acting "mute button" that can silence the acid factory instantly and keep it quiet for longer. One of these new stars is a drug called tegoprazan. But here's the big question: Is this new, faster mute button actually better than the old pause button, and is it worth the extra cost?
This paper is a "rapid health technology assessment," which is basically a super-efficient detective story where researchers gather all the existing clues (studies) to answer that question quickly. The team, led by Lan Liu and colleagues, scoured the globe for every piece of evidence they could find up to December 2025, looking at how tegoprazan stacks up against the old-school PPIs. They didn't just look at whether the drugs worked; they checked if they were safe, if patients could stick to taking them, and whether they were a good deal for the wallet.
So, what did the detectives find? When it comes to healing the damage caused by acid (like fixing a scorched pot), tegoprazan and PPIs are essentially tied. They both do a great job, and it doesn't seem to matter much if you take the drug for a short time or a long time; the result is the same. However, when it comes to kicking out the H. pylori bacteria, tegoprazan shows some really promising signs. The evidence suggests that in certain situations—like when the bacteria are resistant to common antibiotics, or when the treatment lasts for 10 or 14 days—tegoprazan might be slightly more effective at clearing the infection than PPIs, although the difference wasn't statistically significant in the overall analysis. It's like having a specialized tool that shows potential on the toughest, most stubborn stains, even if the final score is a tie.
Safety is where things get a little interesting. Both drugs are generally safe, but they have different "side effects" profiles. Tegoprazan seems to cause fewer of the common, annoying complaints like stomach pain, bloating, diarrhea, headaches, or a weird taste in your mouth compared to PPIs. It's like the new drug is gentler on the rest of your body. However, there is a catch: tegoprazan appears to carry a higher risk of messing with liver function. So, while it might be easier on your stomach, you'd need to keep an eye on your liver, kind of like checking the oil in a high-performance car.
Finally, the team looked at the economics. In a simulation based on the Chinese healthcare system, tegoprazan came out looking like a smart financial choice. It was found to be more cost-effective than both PPIs and another new drug called vonoprazan under specific thresholds used in China. The math showed that for every extra bit of health benefit it provided, the extra cost was very reasonable—well within what experts consider a "good deal" for that specific healthcare system.
In short, the paper concludes that tegoprazan is a strong, non-inferior alternative to the old standards. It works just as well for healing, shows promise for stubborn bacteria in specific scenarios, causes fewer common stomach aches, and offers good value under certain economic conditions. The only warning is to watch out for liver issues. While the evidence is strong, the authors note that we still need more large-scale, real-world studies to be absolutely sure, but for now, tegoprazan looks like a very viable option for taming that overzealous stomach acid chef.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.